Venus Medtech

Venus Medtech is a medical device company dedicated to the minimally invasive treatment of heart valve diseases. Its milestone transcatheter aortic valve product, the VenusA-Valve Percutaneous Interventional Artificial Heart Valve System, was approved by the China Food and Drug Administration (CFDA) on April 25, 2017 (Registration No.: GuoXieZhuZhun 20173460680) and officially launched in China. This product is the first transcatheter valve replacement product in China to receive CFDA approval.